Medicare announces lower prices on 10 common, high-cost drugs
As someone who works in the healthcare industry, specifically in the realm of pharmaceuticals, the recent announcement by Medicare regarding the lowered prices on 10 common, high-cost drugs is monumental. The impact of these price reductions cannot be understated, particularly for older individuals who rely on these medications to manage various health conditions.
One of the most significant changes is the cost reduction for direct acting oral anticoagulants (DOACs) such as apixaban and rivaroxaban, essential for post-hospital care. The cost decrease of 55% and 60% respectively is a game-changer for patients who have had to resort to less optimal options like warfarin due to high prices.… Continue reading
John Q. Hosedrinker